Author | Year | Country | Study design | Setting | Level of healthcare system | HIV prevalence | Type of culture | Type of LPA | Â | Â | Â | Â | Â |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehme [30] | 2011 | Multiplea | Observational | Urban | Mixed | 0.19 | Both | Both | Â | Â | Â | Â | Â |
Chryssanthou [70] | 2011 | Sweden | Observational | Urban | Tertiary | NR | Liquid culture | Direct | Â | Â | Â | Â | Â |
Skenders [71] | 2011 | Latvia | Observational | NR | NR | NR | Liquid culture | Direct | Â | Â | Â | Â | Â |
Hanrahan [40] | 2012 | South Africa | Observational | NR | NR | 0.58 | Liquid culture | Both | Â | Â | Â | Â | Â |
Jacobson [72] | 2012 | South Africa | Observational | Rural | Tertiary | 0.30 | Liquid culture | Indirect | Â | Â | Â | Â | Â |
Lyu [73] | 2013 | South Korea | Observational | Urban | Tertiary | 0.01 | Liquid culture | Direct | Â | Â | Â | Â | Â |
Gauthier [74] | 2014 | Haiti | Observational | Urban | Tertiary | NR | Solid culture | Direct | Â | Â | Â | Â | Â |
Liquid culture | Â | Â | Â | Â | Â | ||||||||
Kipiani [75] | 2014 | Georgia | Observational | Urban | Tertiary | 0.03 | Solid culture | Direct | Â | Â | Â | Â | Â |
Raizada [76] | 2014 | India | Observational | Urban | NR | NR | Solid culture | Direct | Â | Â | Â | Â | Â |
Singla [77] | 2014 | India | Observational | Urban | Tertiary | NR | Both | Direct | Â | Â | Â | Â | Â |
Bablishvili [78] | 2015 | Georgia | Observational | Urban | Tertiary | NR | Solid culture | Direct | Â | Â | Â | Â | Â |
Liquid culture | Â | Â | Â | Â | Â | ||||||||
Cox [39] | 2015 | South Africa | Observational | Urban | Primary | 0.74 | Both | Direct | Â | Â | Â | Â | Â |
Eliseevb [79] | 2016 | Russia | Observational | NR | NR | 0.06 | Solid culture | Direct | Â | Â | Â | Â | Â |
Liquid culture | Â | Â | Â | Â | Â | ||||||||
Evans [80] | 2017 | South Africa | Observational | Urban | Tertiary | 0.89 | NR | NR | Â | Â | Â | Â | Â |
Iruedo [81] | 2017 | South Africa | Observational | Rural | Primary | 0.61 | NR | NR | Â | Â | Â | Â | Â |
Evans [82] | 2018 | South Africa | Observational | Urban | Primary | 0.26 | NR | NR | Â | Â | Â | Â | Â |
Lib,c [43] | 2019 | China | Observational | Urban | Tertiary | NR | Solid culture | Direct | Â | Â | Â | Â | Â |
Jeon [41] | 2020 | South Korea | Observational | Urban | Tertiary | NR | NR | NR | Â | Â | Â | Â | Â |
Ngabonziza [83] | 2020 | Rwanda | Observational | NR | Tertiary | 0.40 | NR | NR | Â | Â | Â | Â | Â |
Shi [42] | 2020 | China | Observational | Urban | Tertiary | NR | Solid culture | Direct | Â | Â | Â | Â | Â |
Author | Year | Diagnostic delay | Treatment initiation delay | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Index | Comparator | Term | Time period | Index | Comparator | Term | Time period | ||||||
n | Median (IQR) (days) | n | Median (IQR) (days) | n | Median (IQR) (days) | n | Median (IQR) (days) | ||||||
Boehme [30] | 2011 | 244 | 63 (38–102) | 356 | 40 (27–53) | Time to detection | Specimen collection to receiving result by clinicians | NR | NR | NR | NR | NR | NR |
Chryssanthou [70] | 2011 | 127 | 21 (13–78) | 127 | 7 (1–16) | Lab processing time | Specimen arrival at lab to report of DST to clinician | NR | NR | NR | NR | NR | NR |
Skenders [71] | 2011 |  | NR | NR | NR | NR | NR | 47 | 40 (23–67) | 22 | 14 (7–22) | Admission to treatment start | Hospital admission to treatment start |
Hanrahan [40] | 2012 | 1176 | 52 (41–77) | 1177 | 26 (11–52) | Test turnaround time | Date of sputum collection to DST results | 26 | 78 (52–93) | 52 | 62 (32–86) | Time to MDR-TB treatment | Date of sputum collection to MDR-TB treatment |
Jacobson [72] | 2012 | 89 | 55 (46–66) | 108 | 27 (20–34) | Lab processing time | Specimen arrival at lab to report of results | 89 | 80 (62–100) | 108 | 55 (37.5–78) | Time to MDR treatment initiation | Specimen collection to MDR treatment initiation |
Lyu [73] | 2013 | 428 | 83 (68–92) | 168 | 12.7 (8–17) | Turnaround time | Test request to reporting of results | NR | NR | NR | NR | NR | NR |
Gauthier [74] | 2014 | 221 | 54 (43–64) | 221 | 7.5 (6.5–8.5) | Turnaround time | NR to time to positivity | NR | NR | NR | NR | NR | NR |
221 | 19 (12–25) | 221 | 7.5 (6.5–8.5) | Turnaround time | NR to time to positivity | NR | NR | NR | NR | NR | NR | ||
Kipiani [75] | 2014 | NR | NR | NR | NR | NR |  | 72 | 83.9 (56–106) | 80 | 18.2 (11–24) | Time to MDR-TB treatment initiation | Sputum collection to start of SLD therapy |
Raizada [76] | 2014 | 248 | 87 (42–208) | 248 | 11 (1–76) | Turnaround testing time | Specimen collection to DST result being available | NR | NR | NR | NR | NR | NR |
Singla [77] | 2014 | 121 | 107 (79–131) | 433 | 5 (3–6) | Diagnostic time in lab | Specimen arrival at lab to MDR-TB report | 51 | 157 (127–200) | 83 | 38 (30–79) | NR | Time from identification patients suspected for MDR-TB to MDR-TB treatment initiation |
Bablishvili [78] | 2015 | 155 | 33 (27–41) | 336 | 5 (3–7) | Time to MTB detection | Sample collection to recorded results | NR | NR | NR | NR | NR | NR |
227 | 9 (7–11) | 336 | 5 (3–7) | Time to MTB detection | Sample collection to recorded results | NR | NR | NR | NR | NR | NR | ||
Cox [39] | 2015 | NR | NR | NR | NR | NR | NR | 95 | 76 (62–111) | 173 | 28 (16–40) | Time to treatment | Time from collection to treatment initiation |
Eliseevb [79] | 2016 | NR | NR | NR | NR | NR | NR | 38 | 90 (76.3–117.3) | 72 | 24 (19–51) | Time to MDR-TB treatment initiation | First visit to treatment |
NR | NR | NR | NR | NR | NR | 58 | 74 (55–99.8) | 72 | 24 (19–51) | Time to MDR-TB treatment initiation | First visit to treatment | ||
Evans [80] | 2017 | NR | NR | NR | NR | NR | NR | 256 | 81 (49–115) | 256 | 38 (23–54) | NR | Sputum collection to treatment initiation |
Iruedo [81] | 2017 | 143 | 45 (39–59) | 28 | 11.5 (8–21) | Time to diagnosis | Sputum collection to issue of report to clinic | 143 | 64 (50–103) | 28 | 29 (14.5–53) | Time to treatment | Sputum collection to treatment initiation |
Evans [82] | 2018 | NR | NR | NR | NR | NR | NR | 7 | 81 (28–97) | 129 | 38 (23–51) | Time to treatment initiation | Specimen collection to treatment initiation |
Lib,c [43] | 2019 | 155 | 53 (49–60) | 155 | 3 (2–4) | Turnaround time | Sample receipt to reporting date of results | NR | NR | NR | NR | NR | NR |
Jeon [41] | 2020 | NR | NR | NR | NR | NR | NR | 263 | 13 (5–25) | 202 | 5 (2–9.3) | Time to MDR treatment initiation | MDR-TB diagnosis to MDR-TB treatment initiation |
Ngabonziza [83] | 2020 | 313 | 87 (78–98) | 197 | 40 (25–55) | RR-TB diagnostic delay | Specimen collection to results being available | NR | NR | NR | NR | NR | NR |
Shi [42] | 2020 | 105 | 62 (53–69) | 113 | 16 (10–19) | NR | NR | 37 | 69 (59–77) | 42 | 19 (14–23) | NR | NR |